Paritaprevir (Standard)

Overview

Paritaprevir (Standard) is the analytical standard of Paritaprevir. This product is intended for research and analytical applications. Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor).

Application

Products | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > 3-Chymotrypsin-Like Protease | Products > Disease Areas > Infection | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Others | Products > Research Areas > Infection | Products > Signaling Pathways > HCV Protease | Products > Signaling Pathways > HCV | Products > Signaling Pathways > SARS-CoV | Products > Signaling Pathways > Reference Standards

Product Information

• Catalog No.: HY-12594R
• CAS No.: 1216941-48-8
• Molecular Formula: C40H43N7O7S
• Molecular Weight: 765.88
• Purity: 98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source